CompletedPhase 2NCT00941811

Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

Studying Vulvar intraepithelial neoplasia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Medical University of Vienna
Principal Investigator: Georg Stingl, Prof.
Medical University of Vienna
Intervention: Imiquimod(drug)
Enrollment: 5 target
Eligibility: 18 years · FEMALE
Timeline: 2008 – 2010

Study locations (1)

Stephan Polterauer, Vienna, Austria

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00941811 on ClinicalTrials.gov

← Back to all trials